PCT No. PCT/GB91/01835 Sec. 371 Date Apr. 30, 1993 Sec. 102(e) Date Apr. 30, 1993 PCT Filed Oct. 18, 1991 PCT Pub. No. WO92/07839 PCT Pub. Date May 14, 1992. (I) A compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein R1 and R2 each independently represent an alkyl group, a ...

This invention encompasses compounds of formula (I) wherein: n is 0, 1 or 2, A is X or Ra is hydrogen or nitro; and R1, R2, X, Y and W are variables. These compounds are useful as intermediates for production of certain cycloalkyl and azacycloalkyl pyrrolopyrimidines which are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs th...

The instant invention is a novel use of known cyclic amino acids. Such compounds, including gabapentin, are useful for treating major and minor forms of depression.

The invention concerns epoxycarbacyclin intermediates, a method for preparing them from the Z-isomers of corresponding carbacyclin precursors, and their use in the preparation of pharmacologically active carbacyclins.

PCT No. PCT/EP91/02048 Sec. 371 Date Apr. 28, 1993 Sec. 102(e) Date Apr. 28, 1993 PCT Filed Oct. 29, 1991 PCT Pub. No. WO92/07904 PCT Pub. Date May 14, 1992.A rubber composition which is the vulcanization reaction product of a rubber, sulfur or a sulfur donor and particular anti-reversion coagents, is disclosed. The anti-reversion coagents only partially react under sulfur-vulcanization reaction c...

PCT No. PCT/SE91/00690 Sec. 371 Date Apr. 16, 1993 Sec. 102(e) Date Apr. 16, 1993 PCT Filed Oct. 15, 1991 PCT Pub. No. WO92/06679 PCT Pub. Date Apr. 30, 1992.A melt granulating method for the production of pellets (spheres) which contain a therapeutically active substance of high-dosage type. The method is characterized by: (i) mechanically working a mixture which contains (a) the active substance...

2095433 9208719 PCTABS00013 Pyrido¢2,3-d!pyrimidin-2,4(1H,3H)-diones are disclosed, having formulas (Ia) and (Ib), in which R1 and R2 stand for H, substituted or unsubstituted alkyl, cycloalkyl; R3 stands for H, substituted or unsubstituted alkyl; R4 stands for H, alkyl, alkoxycarbonyl, (alkylthio)carbonyl, alkoxy(thiocarbonyl), (alkylthio)thiocarbonyl, cyano or aminocarbonyl; or R3 and R4 represe...

PCT No. PCT/GB91/01858 Sec. 371 Date Apr. 26, 1993 Sec. 102(e) Date Apr. 26, 1993 PCT Filed Oct. 23, 1991 PCT Pub. No. WO92/07843 PCT Pub. Date May 14, 1992.Benzofuran-ether-sulphone monomers of formula and ether ketone polymers derived therefrom of formula

An antimicrobial composition comprising an antimicrobial material derived from the plant family Allium together with non-pathogenic microorganisms of at least one species, in which the antimicrobial material is isolated from the plant material in such a way (for example, by freeze-drying of whole cloves) that the material comprises alliin and alliinase and is substantially free of allicin. The com...

A calcium antagonist especially nimodipine, is used for the treatment of demyelinating diseases such as multiple sclerosis. It may be used in combination with an antiviral compound which is active against retroviruses, such as azidothymidine.

A solid surface having anionic groups capable of reacting with imino groups is provided with a hydrophilic outer surface layer comprising a covalently bonded biopolymer by a method selected from the group consisting of: a) reacting a water-soluble conjugate comprising nonionic hydrophilic polymer covalently bonded to a polyethylene imine and at least partly to a biopolymer with anionic groups on t...

The present invention provides the use of a fibroblast growth factor (FGF) for the manufacture of a hypotensive agent for the treatment or prophylaxis of a mammal, including man. Further, the invention has utility in providing a method of reducing blood pressure in a mammal, including man, by administering an effective amount of FGF to a recipient in need of such therapy.

PCT No. PCT/FR91/00805 Sec. 371 Date Jun. 4, 1993 Sec. 102(e) Date Jun. 4, 1993 PCT Filed Oct. 16, 1991 PCT Pub. No. WO92/06666 PCT Pub. Date Apr. 30, 1992.The present invention relates to compositions based on thermal water containing liposomes of thermal water stabilized in a deoxyribonucleic acid (DNA) gel and a process for preparing thereof. The composition is useful in dermatology and cosmeto...

A vaccine suitable for use in inducing immunity to whooping cough in humans comprises a synergistic combination of the 69kDa antigen of Bordetella pertussis and toxoided lymphocytosis promoting factor of Bordetella pertussis.

The present invention relates to novel topical compositions comprising 16,16-disubstituted androstene steroid compounds. Such compositions useful in hair growth and skin disorders.

The use of retinoids to act as skin penetration enhancers is disclosed. Topical compositions of retinoids with 16,16 disubstituted androstene steroids are also disclosed. Such compositions have utility in arresting hair loss and promoting hair growth.

An improved process for the preparation of (4R-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate is described where a hydroxy ester derivative is converted in two steps to the desired product, as well as valuable intermediates used in the process.

The invention concerns the use of Medicago saponins for the preparation of cosmetic or pharmaceutical compositions through the incorporation of 0.01 % to 5 % by weight of a saponin or a corresponding sapogenin, or a plant extract containing same, in particular from Lucerne leaves or roots, to help renew the epidermis, stimulate the regrowth of hair or delay hair loss, or to help combat the effects...

Monocyclic and bicyclic aryl ring compounds having selective LTB4 properties and comprising two ring substituents, the first substituent comprising a lipophilic group and a terminal carboxylic acid or derivative group, and the second substituent comprising an amido group, therapeutic compositions and methods of treatment of disorders which result from LTB4 activity using the mono- and bicyclic ary...

This invention is therapeutically useful 2-aminotetralins and pharmaceutically acceptable acid addition salts thereof of formula (I), wherein R is hydrogen or halogen, wherein R1 is hydrogen, OR4, SR4, CONR5R6, CN, het, C(O)het, CF3, SO2NR5R6, 5-oxazolyl, CSNR5R6, OSO2CF3, wherein R2 and R3 are independently hydrogen, alkyl, alkenyl, alkynyl, (CH2)m-cycloalkyl, (CH2)m-cycloalkenyl, (CH2)m-aryl, (C...